drugset / Trial / NCT05533073

Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in Combination

NCT05533073

Phase 1 Completed 42 enrolled Laboratorios Silanes S.A. de C.V.
RandomizedCrossoverOpen-labelTreatment

Summary

Study carried out in the Clinical and Analytical Unit of the Department of Pharmacology and Toxicology of the Faculty of Medicine of the Autonomous University of Nuevo León, with the objective of comparing the bioavailability (Cmax, AUC) of an oral formulation containing Etoricoxib 90 mg / Tramadol 50 mg in combination with that of two oral formulations, Etoricoxib 90 mg or Tramadol 50 mg, administered as a single dose, in healthy subjects under fasting conditions.

Timeline

Start
2020-08-03
Primary completion
2020-09-07
Completion
2020-11-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etoricoxib Small molecule 90 mg Oral
Comparator Tramadol Other / unclassified 50 mg Oral

Indications

No indication recorded.